Oxford Biomedica Licenses its Gene Delivery Technology to Virxsys
News Mar 13, 2006
The agreement provides Virxsys with rights to utilise this technology in the production process of Virxsys’s anti-HIV/AIDS product VRX496 which is currently in Phase II trials.
Under the agreement, Oxford BioMedica receives an upfront licence fee and annual maintenance payments.
In addition, Oxford BioMedica will receive payments on the achievement of clinical and regulatory milestones by Virxsys and product royalties.
Oxford BioMedica’s CEO, Professor Alan Kingsman, said, "We are delighted to welcome Virxsys to the growing list of Oxford BioMedica’s technology licensees. This agreement further underlines the breadth and strength of our proprietary gene delivery technologies."
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE